Cristian Villanueva

TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.

TL;DR: The results suggest that continued VEGF inhibition with further bevacizumab is a valid treatment option for patients with locally recurrent or metastatic HER2-negative breast cancer whose disease was stabilised or responded to first-line bevacsumab with chemotherapy.

TL;DR: Ribociclib plus letrozole improved progression-free survival vs placebo plus let rozole and was well tolerated in postmenopausal women with HR+, HER2− de novo advanced breast cancer.

TL;DR: This study confirms that discordance in ER and PR receptor expression between the primary breast tumor and the corresponding metastatic lesions is high, whereas HER2 status remains relatively constant.

TL;DR: No change in the cardiac safety comparison, and only three additional cases in which the left ventricular ejection fraction decreased to less than 50% have been reported in the 12-month group, means adjuvant trastuzumab standard duration should remain 12 months.